Scholar Rock (SRRK) Q3 2026 earnings review
Scholar Rock wins US drug approval, while insurance reviews delay sales
Scholar Rock won US approval for its lead muscle drug ahead of schedule and eliminated its near-term funding gap. The Food and Drug Administration cleared Isembyld on September 11 using a backup bottling plant, allowing the drugmaker to ship its first $0.6 million of inventory before quarter-end. Chief executive David L. Hallal signed a November deal to sell the resulting regulatory voucher for $205 million, adding to $414 million in third-quarter cash.
| US Isembyld net revenue | $0.6M Approved Sept 11; first commercial shipments |
|---|---|
| Net loss per share | -$0.81 -$0.90 a year ago (on 16% more shares) |
| Cash plus agreed voucher sale | $619M $414M Q3 cash + $205M voucher deal by our math |
| European regulatory opinion plan | Cut to H1 2027 Resubmitted in Oct with backup factory |
⚖️ Verdict: 🟢 Bullish
The standing case got much better because the approval and the $205 million voucher sale removed both the manufacturing bottleneck and the risk of share-diluting stock sales. Using the same backup plant also allowed the biotech group to resubmit its stalled European application in October. One caution: the company extended its expected wait time between a doctor's prescription and a paid patient infusion to more than 60 to 90 days, up from more than 60 days last quarter.
The question now is how fast early prescriptions turn into paid infusions while insurers review an add-on therapy without a dedicated Medicare billing code until April 2027. If health plans clear claims smoothly, sales will climb in the first quarter; if insurers deny initial requests, revenue will lag until the billing code takes effect in the second quarter. Fourth-quarter product revenue and patient start numbers will provide the first test.
🐂 Bull Case
FDA Approves Isembyld Early via the Backup Factory
Scholar Rock develops medicines that target muscle growth in rare neuromuscular disorders. Its lead drug is Isembyld (apitegromab), an antibody designed to build muscle strength in people with spinal muscular atrophy, or SMA, a genetic disease that causes progressive muscle wasting. For the past year, a manufacturing citation at a third-party plant in Indiana owned by Catalent delayed US approval.
The US Food and Drug Administration approved Isembyld on September 11, nineteen days ahead of the September 30 deadline, using an alternate bottling facility. The agency cleared the medicine broadly for adults and children aged two and older who already take a standard survival motor neuron 2 (SMN2) drug. That broad label removes the standing regulatory and manufacturing bottleneck in the United States.
- Third-quarter product sales: $0.6 million from initial inventory shipped within one week of approval
- Prescribing breadth by October 31: more than one-third of the top 140 US treatment centers enrolled initial patients, plus 9 sites outside the top 140
- Field reach: sales reps engaged more than 95% of the top 140 centers through October, targeting about 6,600 treated US patients
What to watch: fourth-quarter net product revenue and the number of patients receiving commercial infusions after October. Strong revenue growth in the first full quarter on the market would confirm that early prescriptions are turning into paid treatments.
Voucher Sale Adds $205 Million Without New Shares
Funding the commercial rollout without heavy shareholder dilution was a primary concern entering the quarter, because Scholar Rock sold $252 million of new stock through at-the-market offerings over the prior three quarters. When the FDA approved Isembyld in September, it also awarded the biotech company a Rare Pediatric Disease Priority Review Voucher, a transferable pass that speeds up FDA review for another drug.
In November, the drugmaker signed a definitive agreement to sell that voucher for $205 million in cash upon closing. The company said the proceeds will "strengthen the Company’s balance sheet with non-dilutive capital". Alongside the voucher deal, the September approval unlocked access to an extra $150 million loan tranche under its existing credit line with Blue Owl.
- Ending third-quarter cash and securities: $413.6 million, down $78.5 million from the second quarter by our math
- Pro forma cash including the voucher sale: $618.6 million by our math, before drawing any new debt
- Total available liquidity including the $150 million loan tranche: $768.6 million by our math, covering more than two years of current cash burn
What to watch: antitrust clearance and cash receipt from the $205 million voucher sale, plus fourth-quarter share count changes. Closing the voucher deal while halting at-the-market stock sales would prove that commercial operations no longer require equity dilution.
Muscle Pipeline Advances Across Three Clinical Trials
Scholar Rock is expanding its muscle-preserving antibody platform beyond intravenous treatment for older SMA patients. During the third quarter, the Cambridge-based group began dosing patients in FORGE, a 60-patient mid-stage study testing apitegromab in facioscapulohumeral muscular dystrophy (FSHD), another severe muscle-wasting condition. Enrollment is also well advanced in OPAL, a mid-stage study testing the drug in SMA infants under age two.
At the same time, the developer began talks with regulators on an under-the-skin version of apitegromab so patients can take the drug at home instead of visiting an infusion clinic. It is also dosing roughly 76 healthy volunteers in an early-stage study of SRK-439, a next-generation muscle drug, with initial results due by year-end.
What to watch: the regulatory testing requirements for the under-the-skin version of apitegromab and the early SRK-439 data release in early 2027. A fast regulatory path for the at-home shot would protect the SMA franchise from future competitors.
🐻 Bear Case
Insurance Hurdles Delay Infusions by Two to Three Months
"The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA," chief executive David L. Hallal said. Hallal added that "the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community".
However, turning those initial prescriptions into actual revenue is taking longer than previously stated. While 98% of prescribed patients enroll in the company's patient support program, the investor presentation discloses that moving from a doctor's prescription to an infusion "can take more than 60 to 90 days on average at this early stage of launch". Last quarter, chief operating officer Keith Woods put that wait at more than 60 days.
This delay matters because Isembyld is an add-on medicine for patients who already take costly existing SMA drugs, so insurers require strict prior authorizations and hospital formulary reviews. Furthermore, a dedicated Medicare billing code—known as a J-code, which streamlines insurer reimbursement—will not take effect until April 1, 2027, leaving at least two quarters of heavy administrative friction.
What to watch: fourth-quarter and first-quarter product sales alongside any disclosed insurance approval rates before the J-code arrives in April 2027. Sluggish revenue conversion over the next two quarters would show that health plans are resisting the added cost of combination therapy.
Factory Switch Pushes European Decision into Next Year
Scholar Rock wants to sell apitegromab in up to 50 countries, starting with Europe, where it originally planned to win regulatory backing in mid-2026 and launch in Germany during the second half of 2026. Because the European application relied on the troubled Catalent Indiana factory, European reviewers stalled the application while waiting for US inspectors to clear that site.
Instead of waiting further for Catalent, the biotech firm resubmitted its European application in October 2026 using its "alternate fill-finish facility in place of the Catalent Indiana LLC fill-finish facility". European regulators validated the new filing in October, and the drugmaker now expects a formal opinion from the European review committee in the first half of 2027. That timeline confirms a full one-year delay against the original European launch plan.
What to watch: the European review committee opinion in the first half of 2027 and the timing of the subsequent commercial launch in Germany. Any further regulatory questions on the backup factory's data package would push international revenue into 2028.
Risks this quarter didn't answer
Four standing items from our prior analysis received no numbers in the third-quarter release or presentation.
- Drug pricing: the release and slides do not state Isembyld's annual list price or expected insurer discounts; the conference call or first full quarter of sales will test revenue per patient.
- Exact patient enrollment count: slides state that a significant number of patients enrolled by October 31 without giving a headcount; fourth-quarter disclosures will show whether management reports exact patient starts.
- Nine-month operating cash burn: the release omits the cash flow statement, although cash on hand fell by $78.5 million in the quarter by our math; the third-quarter 10-Q filing will give the exact operating cash use.
- FSHD clinical mechanism risk: dosing has started in the 60-patient FORGE study, but only the 12-month muscle volume readout will show whether apitegromab succeeds where a rival muscle drug failed.
👓 Other Themes
Regulatory Incentives Speed Reviews and Add Cash
Government incentives for rare disease treatments shaped Scholar Rock's quarter across three markets. The FDA's rare pediatric program provided the $205 million voucher windfall upon Isembyld's approval, while the agency also granted Fast Track and Orphan Drug status to apitegromab in FSHD. In Japan, regulators accepted the company's SMA filing under priority review, cutting the target review cycle to about nine months, and granted Orphan Drug status.
💲 Other KPIs
Total operating expenses edged down 2.1% from the second quarter and rose 3.0% from a year ago. Research and development spending reached $54.1 million, while selling, general and administrative costs were $52.5 million. Excluding $17.9 million of non-cash stock compensation, cash operating expenses were $88.7 million by our math as the US commercial team took the field.
Share count growth slowed sharply in the third quarter, rising 1.3% from the second quarter compared with a 16.4% increase from a year ago. The year-over-year rise came from earlier at-the-market stock sales and warrant exercises, which narrowed the net loss per share by 10.0% to $0.81 even though total net loss rose 4.9% to $107.2 million.
Total liabilities increased 74.6% from $158.8 million at the end of 2025, and rose 2.8% from $269.8 million in the second quarter. Long-term liabilities stayed at $197.2 million following the first-quarter Blue Owl debt refinancing, while current liabilities rose from $72.2 million in the second quarter to $80.1 million alongside commercial launch activities.
🔮 Guidance
Cut. The drugmaker now expects an opinion from the European review committee in the first half of 2027. In the first quarter of 2026, management targeted a mid-2026 opinion, then left the timeline undated in the second quarter while discussing how to replace the Catalent Indiana plant. Resubmitting the filing in October with the backup factory sets a firm date roughly one year behind the original plan.
Unchanged on internal completion, slightly later on public release. Scholar Rock still expects to have initial data from the 76-volunteer study in hand by the end of 2026, matching its prior target of late 2026, and plans to publish the results in early 2027.
New. Following its Japanese regulatory submission for apitegromab in SMA, the company announced that Japanese reviewers accepted the filing under priority review, which typically takes about nine months. Management anticipates launching the medicine in Japan near the end of 2027.
❓ Key Questions
What is Isembyld's annual US list price and expected discount?
Neither the earnings release nor the presentation states the wholesale price or expected insurer rebates for Isembyld. Without pricing, investors cannot calculate how many infused patients Scholar Rock needs to cover its $106.6 million quarterly operating expense run rate.
How many patients enrolled in Scholar Rock Supports through October?
The presentation says a "significant number of patients enrolled" and that more than a third of top centers wrote prescriptions, but omits exact patient counts. Disclosing start forms and conversion rates is necessary to track demand during the 60-to-90-day reimbursement wait.
Will the $205 million voucher sale end at-the-market stock issuance?
Weighted average shares rose 16.4% over the past year from equity raises, but barely moved in the third quarter. With $413.6 million in cash and $205 million coming from the voucher sale, management can clarify whether it has shut down its equity sales program.
What clinical study will regulators require for under-the-skin apitegromab?
Management has started talking to regulators about the development path for its self-administered subcutaneous formulation after finishing an early-stage study. Whether the FDA requires a small bridging study or a longer efficacy trial will determine when an at-home option reaches patients.